Advertisement

Frequent Behavioural Questions with an HPV-Positive Malignancy of the Head and Neck

  • Gypsyamber D’Souza
  • Anne M. Griffioen
  • Carole Fakhry
Part of the Head and Neck Cancer Clinics book series (HNCC)

Abstract

An initial diagnosis of a head and neck malignancy is sometimes followed by a sense of relief when it becomes known that the malignancy is human papillomavirus (HPV)-positive. This is because HPV-positive malignancy is associated with improved prognosis. However, patients and their partners often wrestle with complex social and behavioural questions. Unfortunately, the answers to many of these questions have not been examined to date. At best, the most appropriate response is to say, ‘We do not know; however, initial evidence suggests that …’, with the caveat that our knowledge of oral HPV infection can only be extrapolated from related research on anogenital HPV infection. Because these cancers have implications for past, present and future relationships between patients and their partners, it is essential that any advice given to patients must be considered carefully.

Keywords

Genital Contact Cervical Cancer Screening Guideline Frequent Behavioural Question Oral Exfoliate Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Muñoz N, Castellsagué X, de González AB, et al. Chapter 1: HPV in the etiology of human cancer. Vaccine. 2006;24 Suppl 3:S3/1–10.Google Scholar
  2. 2.
    Weaver BA. Epidemiology and natural history of genital human papillomavirus infection. J Am Osteopath Assoc. 2006;106(3 Suppl 1):S2–8.PubMedGoogle Scholar
  3. 3.
    Dunne EF, Nielson CM, Stone KM, et al. Prevalence of HPV infection among men: a systematic review of the literature. J Infect Dis. 2006;194:1044–57.PubMedCrossRefGoogle Scholar
  4. 4.
    Woodman CB, Collins S, Winter H, et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet. 2001;357:1831–6.PubMedCrossRefGoogle Scholar
  5. 5.
    Kurose K, Terai M, Soedarsono N, et al. Low prevalence of HPV infection and its natural history in normal oral mucosa among volunteers on Miyako Island, Japan. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004;98:91–6.PubMedCrossRefGoogle Scholar
  6. 6.
    Dalstein V, Riethmuller D, Prétet JL, et al. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int J Cancer. 2003;106:396–403.PubMedCrossRefGoogle Scholar
  7. 7.
    Ho GY, Burk RD, Klein S, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst. 1995;87:1365–71.PubMedCrossRefGoogle Scholar
  8. 8.
    Wallin KL, Wiklund F, Angstrom T, et al. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med. 1999;341:1633–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Trottier H, Burchell AN. Epidemiology of mucosal human papillomavirus infection and associated diseases. Public Health Genomics. 2009;12:291–307.PubMedCrossRefGoogle Scholar
  10. 10.
    D’Souza G, Fakhry C, Sugar EA, et al. Six-month natural history of oral versus cervical human papillomavirus infection. Int J Cancer. 2007;121:143–50.PubMedCrossRefGoogle Scholar
  11. 11.
    Cañadas MP, Bosch FX, Junquera ML, et al. Concordance of prevalence of human papillomavirus DNA in anogenital and oral infections in a high-risk population. J Clin Microbiol. 2004;42:1330–2.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Giuliano AR, Lazcano-Ponce E, Villa LL, et al. The human papillomavirus infection in men study: human papillomavirus prevalence and type distribution among men residing in Brazil, Mexico, and the United States. Cancer Epidemiol Biomarkers Prev. 2008;17:2036–43.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Gillison ML, Broutian T, Pickard RK, et al. Prevalence of oral HPV infection in the United States, 2009–2010. JAMA. 2012;307:693–703.PubMedCrossRefGoogle Scholar
  14. 14.
    D’Souza G, Griffioen AM, Kluz N, et al. Oral HPV prevalence, six-month persistence and incidence among high-risk young adults. In: 28th international papillomavirus conference. Puerto Rico; 2012. p. 215.Google Scholar
  15. 15.
    Beachler DC, D’Souza G, Sugar EA, et al. Natural history of anal versus oral HPV infection in HIV-infected men and women. J Infect Dis. 2013;208:330–9.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    D’Souza G, Agrawal Y, Halpern J, et al. Oral sexual behaviors associated with prevalent oral human papillomavirus infection. J Infect Dis. 2009;199:1263–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Kreimer AR, Alberg AJ, Daniel R, et al. Oral human papillomavirus infection in adults is associated with sexual behavior and HIV serostatus. J Infect Dis. 2004;189:686–98.PubMedCrossRefGoogle Scholar
  18. 18.
    Smith EM, Swarnavel S, Ritchie JM, et al. Prevalence of human papillomavirus in the oral cavity/oropharynx in a large population of children and adolescents. Pediatr Infect Dis J. 2007;26:836–40.PubMedCrossRefGoogle Scholar
  19. 19.
    Kreimer AR, Villa A, Nyitray AG, et al. The epidemiology of oral HPV infection among a multinational sample of healthy men. Cancer Epidemiol Biomarkers Prev. 2011;20:172–82.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Kreimer AR, Hildesheim A, Abrahamson M, et al. Oral HPV persistence at 6- and 12-months among healthy men: The HIM study. In: 26th international papillomavirus conference, Canada; 2010. p. 76.Google Scholar
  21. 21.
    Kero K, Rautava J, Syrjanen K, et al. Oral mucosa as a reservoir of human papillomavirus: point prevalence, genotype distribution, and incident infections among males in a 7-year prospective study. Eur Urol. 2012;62:1063–70.PubMedCrossRefGoogle Scholar
  22. 22.
    D’Souza G, Kreimer AR, Viscidi R, et al. Case–control study of human papillomavirus and oropharyngeal cancer. N Engl J Med. 2007;356:1944–56.PubMedCrossRefGoogle Scholar
  23. 23.
    Smith EM, Ritchie JM, Summersgill KF, et al. Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers. Int J Cancer. 2004;108:766–72.PubMedCrossRefGoogle Scholar
  24. 24.
    Chin-Hong PV, Vittinghoff E, Cranston RD, et al. Age-specific prevalence of anal human papillomavirus infection in HIV-negative sexually active men who have sex with men: the EXPLORE study. J Infect Dis. 2004;190:2070–6.PubMedCrossRefGoogle Scholar
  25. 25.
    Beachler DC, Weber KM, Margolick JB, et al. Risk factors for oral HPV infection among a high prevalence population of HIV-positive and at-risk HIV-negative adults. Cancer Epidemiol Biomarkers Prev. 2012;21:122–33.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Pickard RK, Xiao W, Broutian TR, et al. The prevalence and incidence of oral human papillomavirus infection among young men and women, aged 18–30 years. Sex Transm Dis. 2012;39:559–66.PubMedCrossRefGoogle Scholar
  27. 27.
    Centers for Disease Control and Prevention (CDC). Trends in HIV-related risk behaviors among high school students—United States, 1991–2011. MMWR Morb Mortal Wkly Rep. 2012;61:556–60.Google Scholar
  28. 28.
    Mork J, Lie AK, Glattre E, et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med. 2001;344:1125–31.PubMedCrossRefGoogle Scholar
  29. 29.
    Kreimer AR, Johansson M, Waterboer T, et al. An evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. In: 28th international papillomavirus conference. Puerto Rico; 2012. p. 209.Google Scholar
  30. 30.
    Burchell AN, Winer RL, de Sanjosé S, et al. Chapter 6: epidemiology and transmission dynamics of genital HPV infection. Vaccine. 2006;24 Suppl 3:S3/52–61.Google Scholar
  31. 31.
    Mammas IN, Sourvinos G, Spandidos DA. Human papilloma virus (HPV) infection in children and adolescents. Eur J Pediatr. 2009;168:267–73.PubMedCrossRefGoogle Scholar
  32. 32.
    Watts DH, Koutsky LA, Holmes KK, et al. Low risk of perinatal transmission of human papillomavirus: results from a prospective cohort study. Am J Obstet Gynecol. 1998;178:365–73.PubMedCrossRefGoogle Scholar
  33. 33.
    Rintala MA, Grénman SE, Järvenkylä ME, et al. High-risk types of human papillomavirus (HPV) DNA in oral and genital mucosa of infants during their first 3 years of life: experience from the Finnish HPV Family Study. Clin Infect Dis. 2005;41:1728–33.PubMedCrossRefGoogle Scholar
  34. 34.
    Summersgill KF, Smith EM, Levy BT, et al. Human papillomavirus in the oral cavities of children and adolescents. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001;91:62–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Reiter PL, Pendergraft 3rd WF, Brewer NT. Meta-analysis of human papillomavirus infection concordance. Cancer Epidemiol Biomarkers Prev. 2010;19:2916–31.PubMedCentralPubMedCrossRefGoogle Scholar
  36. 36.
    D’Souza G, Gross ND, Pai SI, et al. Oral human papillomavirus (HPV) infection in HPV-positive patients with oropharyngeal cancer and their partners. J Clin Oncol. 2014;32:2408–15.PubMedCrossRefGoogle Scholar
  37. 37.
    Saslow D, Solomon D, Lawson HW, et al.; American Society for Colposcopy and Cervical Pathology; American Society for Clinical Pathology. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol. 2012;137:516–42.Google Scholar
  38. 38.
    Agrawal Y, Koch WM, Xiao W, et al. Oral human papillomavirus infection before and after treatment for human papillomavirus 16-positive and human papillomavirus 16-negative head and neck squamous cell carcinoma. Clin Cancer Res. 2008;14:7143–50.PubMedCentralPubMedCrossRefGoogle Scholar
  39. 39.
    Coutlée F, Trottier AM, Ghattas G, et al. Risk factors for oral human papillomavirus in adults infected and not infected with human immunodeficiency virus. Sex Transm Dis. 1997;24:23–31.PubMedCrossRefGoogle Scholar
  40. 40.
    Winer RL, Hughes JP, Feng Q, et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med. 2006;354:2645–54.PubMedCrossRefGoogle Scholar
  41. 41.
    Huang LW, Seow KM. Oral sex is a risk factor for human papillomavirus-associated nasopharyngeal carcinoma in husbands of women with cervical cancer. Gynecol Obstet Invest. 2010;70:73–5.PubMedCrossRefGoogle Scholar
  42. 42.
    Hemminki K, Dong C. Cancer in husbands of cervical cancer patients. Epidemiology. 2000;11:347–9.PubMedCrossRefGoogle Scholar
  43. 43.
    Hemminki K, Dong C, Frisch M. Tonsillar and other upper aerodigestive tract cancers among cervical cancer patients and their husbands. Eur J Cancer Prev. 2000;9:433–7.PubMedCrossRefGoogle Scholar
  44. 44.
    Haddad R, Crum C, Chen Z, et al. HPV16 transmission between a couple with HPV-related head and neck cancer. Oral Oncol. 2008;44:812–5.PubMedCrossRefGoogle Scholar
  45. 45.
    Capone RB, Pai SI, Koch WM, et al. Detection and quantitation of human papillomavirus (HPV) DNA in the sera of patients with HPV-associated head and neck squamous cell carcinoma. Clin Cancer Res. 2000;6:4171–5.PubMedGoogle Scholar
  46. 46.
    Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367:1247–55.PubMedCrossRefGoogle Scholar
  47. 47.
    Garland SM, Hernandez-Avila M, Wheeler CM, et al.; Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356:192843.Google Scholar
  48. 48.
    Centers for Disease Control and Prevention (CDC). FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010;59:630–2.Google Scholar
  49. 49.
    Centers for Disease Control and Prevention (CDC). FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010;59:626–9.Google Scholar
  50. 50.
    Gillison ML. Human papillomavirus-related diseases: oropharynx cancers and potential implications for adolescent HPV vaccination. J Adolesc Health. 2008;43(4 Suppl):S52–60.PubMedCentralPubMedCrossRefGoogle Scholar
  51. 51.
    D’Souza G, Dempsey A. The role of HPV in head and neck cancer and review of the HPV vaccine. Prev Med. 2011;53 Suppl 1:S5–11.PubMedCentralPubMedCrossRefGoogle Scholar
  52. 52.
    Rose RC, Lane C, Wilson S, et al. Oral vaccination of mice with human papillomavirus virus-like particles induces systemic virus-neutralizing antibodies. Vaccine. 1999;17:2129–35.PubMedCrossRefGoogle Scholar
  53. 53.
    Suzich JA, Ghim SJ, Palmer-Hill FJ, et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A. 1995;92:11553–7.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Carole Fakhry, Gypsyamber D’Souza, Rehan Kazi and Raghav C. Dwivedi  2015

Authors and Affiliations

  • Gypsyamber D’Souza
    • 1
  • Anne M. Griffioen
    • 2
  • Carole Fakhry
    • 3
  1. 1.Department of EpidemiologyJohns Hopkins Bloomberg School of Public HealthBaltimoreUSA
  2. 2.Department of EpidemiologyUniversity of Minnesota Medical SchoolDuluthUSA
  3. 3.Department of Otolaryngology-Head and Neck SurgeryThe Johns Hopkins University School of MedicineBaltimoreUSA

Personalised recommendations